FASLG and cancer: The Augusta University Research Institute, Inc. has developed a new inhibitor for HMTase SUV39H1 that appears to be useful in activating certain cytotoxic T-cell effectors, such as CD95L, thereby reversing cancer-induced immune suppression and promoting the killing of cancer cells by cytotoxic T cells (US20190084987) [301].